Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity

被引：29

作者：

Hariwig, Udo F. ^{[1
]}

Nonn, Marion ^{[1
]}

Khan, Shamsul ^{[1
]}

Link, Irina ^{[1
]}

Huber, Christoph ^{[1
]}

Herr, Wolfgang ^{[1
]}

机构：

[1] Johannes Gutenberg Univ Mainz, Sch Med, Dept Med Hematol & Oncol 3, D-55131 Mainz, Germany

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2008年 / 14卷 / 01期

关键词：

lymphocyte graft engineering; T cell depletion; allodepletion;

D O I：

10.1016/j.bbmt.2007.10.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In allogeneic hematopoietic stem cell transplantation (AHSCT) graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect are closely but not invariably linked. Thus, harnessing donor lymphocyte mediated GVL immunity and separating it from GVHD is of particular interest. Based on results obtained in murine models we have explored the CD95-mediated activation-induced cell death (AICD) strategy to selectively deplete alloreactivity in human donor T lymphocytes in vitro. Following stimulation of CD3(+) T cells isolated from HILA-A*0201-positive donors with HLA or minor histocompatibility antigen mismatched hematopoietic or nonhematopoietic cells in the presence of agonistic anti-CD95 antibody, we achieved efficient and selective allodepletion across major and minor histocompatibility mismatched barriers. Residual alloreactivity was in the range of 10% and 25% using hematopoietic cells and primary keratinocytes as alloantigen-presenting cells, respectively. CD8(+) T cells specific for HLA-A*0201-associated cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Wilms tumor 1 peptide epitopes were retained at significant numbers within the allodepleted donor lymphocyte subsets. Additionally, CD4(+) FoxP3(+) regulatory T cells persisted after the allodepletion procedure. Our results show that AICD induced by an agonistic anti-CD95 antibody might be useful to generate allodepleted donor lymphocyte products with preserved beneficial immune functions for patients undergoing AHSCT. (c) 2008 American Society for Blood and Marrow Transplantation.

引用

页码：99 / 109

页数：11